| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5912678 | Multiple Sclerosis and Related Disorders | 2014 | 7 Pages |
Abstract
The sample sizes derived are in a range that makes MTR a feasible outcome measure for proof-of-concept trials of putative therapies achieving remyelination in MS lesions.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Genetics
Authors
D.R. Altmann, T. Button, K. Schmierer, K. Hunter, D.J. Tozer, C.A. Wheeler-Kingshott, A. Coles, D.H. Miller,